X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CIPLA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CIPLA ORCHID PHARMA LTD/
CIPLA
 
P/E (TTM) x -0.8 46.0 - View Chart
P/BV x 0.6 3.8 14.9% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ORCHID PHARMA LTD   CIPLA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CIPLA
Mar-17
ORCHID PHARMA LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs194622 31.2%   
Low Rs35458 7.6%   
Sales per share (Unadj.) Rs276.5181.9 152.0%  
Earnings per share (Unadj.) Rs-79.212.9 -615.4%  
Cash flow per share (Unadj.) Rs-43.529.3 -148.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9155.7 34.6%  
Shares outstanding (eoy) m70.45804.51 8.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.43.0 13.9%   
Avg P/E ratio x-1.442.0 -3.4%  
P/CF ratio (eoy) x-2.618.4 -14.3%  
Price / Book Value ratio x2.13.5 61.2%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m8,067434,516 1.9%   
No. of employees `0002.823.0 12.2%   
Total wages/salary Rs m2,52726,338 9.6%   
Avg. sales/employee Rs Th6,956.16,349.1 109.6%   
Avg. wages/employee Rs Th902.51,143.0 79.0%   
Avg. net profit/employee Rs Th-1,993.0449.3 -443.5%   
INCOME DATA
Net Sales Rs m19,477146,302 13.3%  
Other income Rs m4072,287 17.8%   
Total revenues Rs m19,884148,589 13.4%   
Gross profit Rs m1,10324,758 4.5%  
Depreciation Rs m2,51913,229 19.0%   
Interest Rs m5,2271,594 327.9%   
Profit before tax Rs m-6,23612,222 -51.0%   
Minority Interest Rs m200-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,798 -7.0%   
Profit after tax Rs m-5,58010,354 -53.9%  
Gross profit margin %5.716.9 33.5%  
Effective tax rate %2.014.7 13.6%   
Net profit margin %-28.77.1 -404.8%  
BALANCE SHEET DATA
Current assets Rs m11,01487,370 12.6%   
Current liabilities Rs m32,06033,081 96.9%   
Net working cap to sales %-108.137.1 -291.2%  
Current ratio x0.32.6 13.0%  
Inventory Days Days9587 109.1%  
Debtors Days Days3462 53.9%  
Net fixed assets Rs m29,440111,567 26.4%   
Share capital Rs m7051,609 43.8%   
"Free" reserves Rs m2,043123,645 1.7%   
Net worth Rs m3,800125,254 3.0%   
Long term debt Rs m9,01836,454 24.7%   
Total assets Rs m46,510209,532 22.2%  
Interest coverage x-0.28.7 -2.2%   
Debt to equity ratio x2.40.3 815.4%  
Sales to assets ratio x0.40.7 60.0%   
Return on assets %-0.85.7 -13.3%  
Return on equity %-146.98.3 -1,776.5%  
Return on capital %-3.78.5 -43.9%  
Exports to sales %37.934.2 110.7%   
Imports to sales %22.68.3 271.2%   
Exports (fob) Rs m7,37850,050 14.7%   
Imports (cif) Rs m4,40612,203 36.1%   
Fx inflow Rs m7,51351,066 14.7%   
Fx outflow Rs m5,64917,678 32.0%   
Net fx Rs m1,86533,388 5.6%   
CASH FLOW
From Operations Rs m1,68223,824 7.1%  
From Investments Rs m-9,860-13,127 75.1%  
From Financial Activity Rs m6,644-13,239 -50.2%  
Net Cashflow Rs m-1,535-2,478 61.9%  

Share Holding

Indian Promoters % 32.3 16.0 201.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.6 12.2 37.7%  
FIIs % 3.3 23.7 13.9%  
ADR/GDR % 4.6 1.1 418.2%  
Free float % 55.3 26.2 211.1%  
Shareholders   84,811 161,166 52.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 16, 2017 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - NOVARTIS COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS